CPHI 2025: Redefining Nutraceuticals with New Delivery Formats and Pharma-Grade Standards
The lines between pharmaceuticals and nutraceuticals are increasingly merging. At the CPHI 2025 trade show, innovations showcased how these industries are coming together in both efficacy and delivery formats.
Industry Collaboration and Insights
On the showroom floor, Nutrition Insight explored this convergence alongside companies such as PharmaLinea, Lubrizol, Sirio, Corbion, and Bioiberica, focusing on new delivery approaches.
PharmaLinea's Perspective on Quality and Efficacy
Matevž Ambrožič, marketing director at PharmaLinea, emphasized that the pharmaceutical sector is pushing the supplement market toward higher standards. He stated:
“They have substantial marketing power and are applying pressure to the supplement industry to develop higher quality and proof of efficacy.”
Clinical Substantiation as a Core Focus
PharmaLinea is prioritizing clinical validation as crucial to achieving pharmaceutical-grade supplements. Ambrožič explained:
“While branded ingredients are increasingly backed by clinical studies, finished-product clinical validation is still rare — and that’s where we focus.”
He also shared that PharmaLinea currently has several finished-product lines supported by clinical studies, with many more trials underway. Their goal is to obtain clinical substantiation for the entire portfolio.
“That’s our way of adapting to the future that will probably be more pharmaceutical-grade standards — at least for a part of the supplement industry.”
Summary
The nutraceutical industry is evolving toward pharmaceutical-level quality, leveraging clinical studies and innovative delivery formats to meet rising expectations.